TY - JOUR
T1 - Prostate cancer incidence and aggressiveness in appalachia versus non-appalachia populations in Pennsylvania by urban-rural regions, 2004–2014
AU - McDonald, Alicia C.
AU - Wasserman, Emily
AU - Lengerich, Eugene J.
AU - Raman, Jay D.
AU - Geyer, Nathaniel R.
AU - Hohl, Raymond J.
AU - Wang, Ming
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/7
Y1 - 2020/7
N2 - Background: Few studies have examined prostate cancer incidence and aggressiveness in urban-rural Appalachian populations. We examined these rates in urban-rural Appalachia and non-Appalachia Pennsylvania (PA), and the association between these areas and more aggressive prostate cancer at diagnosis. Methods: Men, ages ≥ 40 years with a primary prostate cancer diagnosis, were identified from the 2004–2014 Pennsylvania Cancer Registry. Age-adjusted incidence rates for prostate cancer and more aggressive prostate cancer at diagnosis were calculated by urban-rural Appalachia status. Multivariable Poisson regressions were conducted. Multiple logistic regressions were used to examine the association between the geographic areas and more aggressive prostate cancer, after adjusting for confounders. Results: There were 94,274 cases, ages 40–105 years, included. Urban non-Appalachia had the highest 2004–2014 age-adjusted incidence rates of prostate cancer and more aggressive prostate cancer (293.56 and 96.39 per 100,000 men, respectively) and rural Appalachia had the lowest rates (256.48 and 80.18 per 100,000 men, respectively). Among the cases, urban Appalachia were more likely [OR ¼ 1.12; 95% confidence interval (CI) ¼ 1.08–1.17] and rural Appalachia were less likely (OR ¼ 0.92; 95% CI ¼ 0.87–0.97) to have more aggressive prostate cancer at diagnosis compared with urban non-Appalachia. Conclusions: Lower incidence rates and the proportion of aggressive disease in rural Appalachia may be due to lower prostate cancer screening rates. More aggressive prostate cancer at diagnosis among the cases in urban Appalachia may be due to exposures that are prevalent in the region. Impact: Identifying geographic prostate cancer disparities will provide information to design programs aimed at reducing risk and closing the disparity gap.
AB - Background: Few studies have examined prostate cancer incidence and aggressiveness in urban-rural Appalachian populations. We examined these rates in urban-rural Appalachia and non-Appalachia Pennsylvania (PA), and the association between these areas and more aggressive prostate cancer at diagnosis. Methods: Men, ages ≥ 40 years with a primary prostate cancer diagnosis, were identified from the 2004–2014 Pennsylvania Cancer Registry. Age-adjusted incidence rates for prostate cancer and more aggressive prostate cancer at diagnosis were calculated by urban-rural Appalachia status. Multivariable Poisson regressions were conducted. Multiple logistic regressions were used to examine the association between the geographic areas and more aggressive prostate cancer, after adjusting for confounders. Results: There were 94,274 cases, ages 40–105 years, included. Urban non-Appalachia had the highest 2004–2014 age-adjusted incidence rates of prostate cancer and more aggressive prostate cancer (293.56 and 96.39 per 100,000 men, respectively) and rural Appalachia had the lowest rates (256.48 and 80.18 per 100,000 men, respectively). Among the cases, urban Appalachia were more likely [OR ¼ 1.12; 95% confidence interval (CI) ¼ 1.08–1.17] and rural Appalachia were less likely (OR ¼ 0.92; 95% CI ¼ 0.87–0.97) to have more aggressive prostate cancer at diagnosis compared with urban non-Appalachia. Conclusions: Lower incidence rates and the proportion of aggressive disease in rural Appalachia may be due to lower prostate cancer screening rates. More aggressive prostate cancer at diagnosis among the cases in urban Appalachia may be due to exposures that are prevalent in the region. Impact: Identifying geographic prostate cancer disparities will provide information to design programs aimed at reducing risk and closing the disparity gap.
UR - http://www.scopus.com/inward/record.url?scp=85087470042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087470042&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-19-1232
DO - 10.1158/1055-9965.EPI-19-1232
M3 - Article
C2 - 32277006
AN - SCOPUS:85087470042
SN - 1055-9965
VL - 29
SP - 1365
EP - 1373
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 7
ER -